Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

NCT00079716 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: SGN-40 (anti-huCD40 mAb)

Sponsor

Seagen Inc.

Collaborators

[object Object]